Castle Biosciences, Inc. · NASDAQ:CSTL

Castle Biosciences — Technical Presentation (June 2022)

5 slides from Castle Biosciences's technical presentation, June 2022

1. Slide 1: Uveal Melanoma Patient Attitudes Towards Prognostic Testing Using Gene Expression Profiling

   Uveal Melanoma Patient Attitudes Towards Prognostic Testing Using Gene Expression Profiling Basil K Williams, Jr, MD1, Jennifer J Siegel, PhD2, Katherina M Alsina, PhD2, Lauren Johnston, MSW3, Amanda Sisco, MA4, Kyleigh LiPira, MBA3, Sara M Selig, MD, MPH3, and Peter G Hovland, MD, PhD4 1University

2. Slide 2: Background and Survey Study Design

   Background and Survey Study Design › Prognostic tests including 15-gene expression profile (15-GEP), chromosome 3 status, and BAP1 mutations are used across the U.S in the management of newly diagnosed uveal melanoma (UM) › The objective of this study was to understand UM patient experiences followi

3. Slide 3: Desire For and Use of Prognostic Testing

   Desire For and Use of Prognostic Testing A. B. N=177 3

4. Slide 4: Patients Value Test Results: 'What do you feel you gained MOST...?'

   Patients Value Test Results: ‘What do you feel you gained MOST...?’ › …from any prognostic test: › ...from 15-GEP: patients with a Class 1A increased knowledge and understanding result (low risk) gained a sense of relief from uncertainty about the future A. B. low risk (n=85) intermediate risk (n=13

5. Slide 5: Low Decision Regret After Prognostic Testing, Regardless of 15-GEP Class Result

   Low Decision Regret1 After Prognostic Testing, Regardless of 15- GEP Class Result › Patients had significantly more decision › For 15-GEP-tested patients, no significant regret if they opted out of prognostic difference in decision regret was found across testing all Class results A. B. Increasing R

Castle Biosciences — Technical Presentation (June 2022) on 6ix